Fondazione Poliambulanza Istituto Ospedaliero Report issue

Foundation Phase 2 Phase 4

Organization Overview

First Clinical Trial
2008
NCT00665119
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Fondazione Poliambulanza Istituto Ospedaliero

Active Ingredients

Drugs in Phase 4 Trials (1)

remifentanil (ultiva) (1 trial)

Drugs in Phase 2 Trials (1)

evolocumab (repatha) (1 trial)

Drugs in Other Trials (1)

glucose (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Infarction (Phase 2)

Myocardial Infarction (Phase 2)

Pulmonary Valve Insufficiency (Phase 4)

Respiratory Insufficiency (Phase 4)

ST Elevation Myocardial Infarction (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 3